Effectiveness and continuation rates of the etonogestrel‐subdermal contraceptive implant versus short‐acting contraceptive methods offered at no cost in Campinas, Brazil
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15415 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Montas Laporte und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Desogestrel, Contraceptive Agents, Female, Drug Implants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: FAPESP, CNPq, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Objectives
To compare the efficacy, reasons for discontinuation and continuation rates of the etonogestrel (ENG)‐subdermal contraceptive implant when offered at no cost, and the basis of free choice versus short‐acting reversible contraceptive (SARC) methods including combined oral contraceptives (COCs), once‐a‐month injectables, vaginal ring, and patch.
Methods
We conducted a prospective study at the University of Campinas, Brazil, involving women aged 18 to 40 years. They were counseled on various contraceptive methods before entering the study and followed up every 3 months for up to 24 months. Satisfaction was assessed using a Likert scale. Survival rates were estimated using the Kaplan–Meier test, and curve comparisons were performed using the log‐rank test.
Results
We enrolled 609 women including 358/609 women (58.8%) who chose the ENG‐implant and 251/609 (41.2%) who chose SARC methods. Contraceptive failure and all other reasons for discontinuation were significantly higher in SARC users compared to the ENG‐implant users ( P < 0.001 and P = 0.002, respectively). The continuation rate was higher among ENG‐implant users (89.9% and 75.4%) compared to SARC methods users (27.2% and 15.9%) up to 1 and 2 years after study initiation, respectively. Satisfaction was high in both groups (>82%).
Conclusions
The ENG‐implant showed higher contraceptive effectiveness and higher continuation rates than SARC methods up to 2 years after study initiation. Furthermore, users from both groups were highly satisfied with their contraceptive. The main reason for discontinuing use of the ENG‐implant was bothersome uterine bleeding, while for SARC methods it was for personal reasons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
ORCID-Profile: Luis Bahamondes
Förderung
- FAPESP
- CNPq
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Laporte, M., Marcelino, A. C., da Cunha Pereira, P., Espejo-Arce, X., Juliato, C. T., & Bahamondes, L. (2024). Effectiveness and continuation rates of the etonogestrel‐subdermal contraceptive implant versus short‐acting contraceptive methods offered at no cost in Campinas, Brazil. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15415
Vancouver
Laporte M, Marcelino AC, da Cunha Pereira P, Espejo-Arce X, Juliato CT, Bahamondes L. Effectiveness and continuation rates of the etonogestrel‐subdermal contraceptive implant versus short‐acting contraceptive methods offered at no cost in Campinas, Brazil. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15415
BibTeX
@article{Laporte2024,
author = {Laporte, Montas and Marcelino, Ana C and da Cunha Pereira, Paula and Espejo-Arce, Ximena and Juliato, Cassia T and Bahamondes, Luis},
title = {Effectiveness and continuation rates of the etonogestrel‐subdermal contraceptive implant versus short‐acting contraceptive methods offered at no cost in Campinas, Brazil},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15415}
}
EUVIMED